<DOC>
	<DOCNO>NCT02370160</DOCNO>
	<brief_summary>This phase I/II study DT2219 treatment relapse refractory CD19 ( + ) and/or CD 22 ( + ) B-lineage leukemia lymphoma . The study consist two phase - phase I dose/schedule find component use maximum tolerate dose identify previous phase I study , high number dose two-stage phase II extension component confirm safety make preliminary determination activity level disease use dose identified phase I .</brief_summary>
	<brief_title>HM2014-26 DT2219 Relapsed Refractory B-Lineage Leukemia Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<criteria>Histologic verification Bcell lineage leukemia B cell nonHodgkin lymphoma evidence relapse/refractory disease presence CD19 and/or CD22 flow cytometry immunohistochemistry bone marrow aspirate , peripheral blood node/tumor biopsy Relapsed refractory disease fail conventional therapy therapy higher priority Karnofsky Performance status ≥ 60 % , less 16 year age , Lansky Play Score ≥ 60 ( appendix II ) Recovered effect prior therapy Peripheral blast count 50 x 109/L Adequate organ function within 14 day ( 30 day cardiac pulmonary ) treatment start Women childbearing potential men advise agree practice effective method contraception course study Voluntary write consent appropriate parent/guardian consent minor information sheet participant &lt; 18 year age Presence leukemic infectious pulmonary parenchymal disease Presence active CNS leukemia Presence uncontrolled systemic infection Documented uncontrolled seizure disorder seizure disorder control medication Active neurologic disorder peripheral neuropathy alone exclude patient Documented penicillin cephalosporin allergy Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>